Nexalin Technology, Inc. has 2 Schedule 13D or 13G filings on record since 2026-08-27. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Alumni Capital LP | 9.99% | 2,493,075 | SCHEDULE 13G, 2026-08-27 | 2026-08-19 |
| Greenlight Ventures, LLC | 5.6% | 1,385,246 | SCHEDULE 13D, 2026-09-03 | 2026-08-18 |
Purpose of Transaction (Item 4)
Greenlight Ventures, LLC
The Reporting Person acquired the Consideration Shares as consideration for the sale of PONM to the Issuer pursuant to the Purchase Agreement described in Item 3, and not by purchase for cash in the open market or otherwise. GLV and the Issuer are also parties to a Collaboration Agreement dated May 14, 2026 (the "Collaboration Agreement"), under which GLV provides the Issuer with operational, technical and strategic support relating to the continued development, compliance and commercialization of the Issuer's cranial electrotherapy stimulation technologies, in exchange for a fee of $10,000 per month over an initial term of 24 months. GLV entered into the Collaboration Agreement in its capacity as a service provider and technology counterparty. Dr. David Owens, a member of the Issuer's board of directors and the Issuer's Chief Medical Officer, holds a minority ownership interest in GLV. GLV has no right under the Purchase Agreement, the Collaboration Agreement or otherwise to designate or nominate any member of the Issuer's board of directors. The Reporting Person intends to review its investment in the Issuer on a continuing basis and may, from time to time and at any time, depending on market conditions, the Issuer's business, financial condition and prospects, the Reporting Person's own liquidity and investment considerations, and other factors the Reporting Person deems relevant, acquire additional shares of Common Stock or other securities of the Issuer, or dispose …The first part of Item 4 of the SCHEDULE 13D filed 2026-09-03; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-08-27 | Alumni Capital LP | 9.99% | SCHEDULE 13G |
| 2026-09-03 | Greenlight Ventures, LLC | 5.6% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for Nexalin Technology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.